What ovulation-rate change has actually been published in PCOS cohorts?

I have the full paper rather than the abstract, and the supplementary appendix.

I want to understand what this actually establishes, as opposed to what it is being used to imply.

My concern is that I am being invited to draw a conclusion the data does not support.

Which parts of this are informative and which are decoration?

The honest answer is that there is good reason to expect benefit on the metabolic axis and thin direct evidence on the reproductive one.

Weight reduction of five to ten per cent has been associated in the older literature with restored ovulatory function in a meaningful fraction of people with this diagnosis, which is the mechanistic bridge the current interest rests on.

Stated carefully, metformin remains the comparator with the longest evidence base in this condition, and any claim that a newer agent is superior needs a head-to-head trial rather than cross-study comparison.

The evidence gap between metabolic and reproductive endpoints in this condition is real, and inference across it should be labelled as inference.

Free androgen changes can come from the binding protein rather than from production. Read both numbers.

The relevant detail is that this is an area where the mechanistic argument is stronger than the trial evidence, and it is worth saying so plainly rather than dressing up the inference.

Free androgen index responds to sex-hormone-binding globulin, which itself rises as insulin resistance falls. So an androgen improvement can appear without any change in total testosterone production, purely through the binding protein.

Cycle regularity is a slow endpoint. Three to six months is the minimum window in which a change would be interpretable, and shorter studies are measuring noise.

Nothing here is medical advice. Anyone of reproductive age has a contraception question here that a forum cannot answer.

Six months is the minimum honest window for a cycle-regularity claim.

Answer first: most of the metabolic evidence here is indirect, drawn from insulin-resistance and weight endpoints in populations that overlap with this one rather than from dedicated trials.

Restored ovulation is a fertility consideration in both directions, and any discussion of this class in a population of reproductive age has to acknowledge the contraception question rather than route around it.

The relevant detail is that the Rotterdam criteria allow several combinations of the three diagnostic features, so a study enrolling on one combination reports on a different population from one enrolling on another.

The caveat is substantial: this is a diagnosis with reproductive, dermatological and metabolic dimensions, and it needs an actual clinician rather than a mechanism argument.

Separate metabolic, reproductive and dermatological endpoints before reading any claim about this condition.

On the detail: the fertility question is a separate one again and carries a contraception consideration that changes the whole risk calculation.

Insulin resistance measured by HOMA-IR improves alongside weight in this class, and HOMA-IR is a fasting-sample surrogate rather than a clamp measurement — adequate for tracking, weak for comparing across studies.

Research-use material of unverified content is not a treatment for anything, and the category difference matters more here than usual.

Check which diagnostic criteria a study used before comparing it with another.

Start with the phenotype. This is a heterogeneous diagnosis with distinct presentations, and evidence about one presentation does not transfer cleanly to another.

Hirsutism and acne respond on the timescale of the hair growth cycle, which is months, so early absence of change says nothing.

Dedicated randomised evidence for this class in this diagnosis is limited and mostly small; the strong evidence is for the metabolic endpoints in adjacent populations.

The mechanism is plausible; the direct evidence is thin. Both statements are true at once.